70 results
8-K
EX-99.1
MBRX
Moleculin Biotech Inc
7 May 24
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
8:55am
” for intensive chemotherapy). Moleculin continues to recruit 1st line subjects into MB-106 to provide data for a possible future confirmatory Phase 3 clinical
424B3
MBRX
Moleculin Biotech Inc
16 Feb 24
Prospectus supplement
5:19pm
, which may make it difficult to predict our future performance.
Our ability to successfully commence and recruit subjects for a potential Phase 2 COVID-19 … and availability of clinical trial sites for prospective subjects;
our ability to recruit clinical trial investigators with the appropriate competencies
8-K
EX-99.1
pjf73gn
24 Jan 24
Regulation FD Disclosure
8:50am
424B5
rbjkcjzc 8m6d
22 Dec 23
Prospectus supplement for primary offering
5:00pm
8-K
EX-99.1
nbtt3yxlpby4hic
13 Nov 23
Regulation FD Disclosure
8:05am
8-K
EX-99.1
2shlj4zav0fai4l13tj
10 Nov 22
Moleculin Reports Third Quarter 2022 Financial Results and Provides Pipeline Update
4:11pm
8-K
EX-99.1
84u46bh53xc0h4bo
14 Oct 22
Moleculin Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
8:40am
8-K
EX-99.1
nibhaay6i4n
19 Aug 22
Moleculin Announces Completion of Third Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
8:40am
8-K
EX-99.1
iaz7z
15 Aug 22
Moleculin Reports Second Quarter 2022 Financial Results and Provides Programs Update
8:48am
8-K
EX-99.1
8ssuq k04tje13f
8 Jul 22
Cohort in Phase 1a Clinical Trial of WP1122 in the UK
8:37am